MMpredict video for project closure

This video is the result of the collaborative MMpredict initiative dedicated to develop a personalised medicine tool that predicts the most effective treatment strategy for individual Multiple Myeloma patients. In this video a myeloma expert from the US, Dr. Usmani...

CORDIS website publication about MMpredict

Multiple myeloma is caused by the abnormal proliferation of plasma cells which produce antibodies as part of the organism’s natural defence. Although treatment options have expanded over the years, it remains incurable, and patients often receive multiple treatments...

Final periodic report summary

Summary of the context and overall objectives of the project The Horizon 2020 MMpredict initiative was started on November 1st 2016 and included the following consortium partners: SkylineDx, the Department of Haematology of the Erasmus University Medical Centre...

Official MMpredict project end date

After more than 4 years of research, the H2020-funded MMpredict project is successfully implemented and officially concluded as of November 1st, 2020. However, research in the field of multiple myeloma should never stop. Therefore we'll host a subsequent consortium...

The MMpredict duration is extended with 6 months due to the COVID-19 outbreak

The European Commission has validated the amendment request of the MMpredict consortium to extend the project duration with 6 month to 31th of October 2020. Due to the COVID-19 outbreak the finalization of the project was hampered since all planned interactions and...

Webinar on personalized treatment in Multiple Myeloma and AL Amyloidosis: how far are we?

Watch the interesting webinar on personalized medicine organized by Myeloma Patients Europe (MPE). In this webinar, Dr. Francesca Bonello from the Università degli Studi di Torino, Turin, Italy – provided examples of the individualized therapy options including future...

Poster presentation during the 17th International Myeloma Workshop

Validation of SKY92 high and low risk prognostication in a retrospective, multinational cohort of 155 non-trial multiple myeloma patients Yan-Ting Chen1, Erik T. Valent1, Erik H. van Beers1, Rowan Kuiper1, Stefania Oliva2, Torsten Haferlach3, Wee-Joo Chng4, Martin H....

Dr. Annemieke Van Dongen-Leunis from the Erasmus School of Health Policy and Management, explains the main results of two posters presented during the 24th European Hematology Association congress

In two video interviews - recorded by the Myeloma Patients Europe - Dr. Annemieke Van Dongen-Leunis from the Erasmus School of Health Policy and Management, Erasmus University Rotterdam, explains the results of the research conducted within the MMpredict consortium....

Webinar on personalised medicine in multiple myeloma

Watch the interesting webinar on personalised medicine organized by Myeloma Patients Europe (MPE). In this webinar, Dr Annemiek Broijl from the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands - provided examples of the individualized...

Fifth H2020 MMpredict consortium meeting in Amsterdam

One day in advance of the 24th EHA congress in Amsterdam, The Netherlands, we have had the opportunity to host our fifth HORIZON 2020 MMpredict consortium meeting. During this interactive session valuable input was exchanged amongst the project partners. We would like...

Project Partners

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 701143

© MMH2020